In a 26-week phase 2 study involving patients with obesity and T2DM, treatment with tirzepatide dose-dependently decreased the circulating levels of specific biomarkers of inflammation and endothelial dysfunction previously associated with cardiovascular events, suggesting a net improvement in the cardiovascular risk profile of these patients.37 In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline and 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.37 After 26 weeks, tirzepatide treatment at doses of 10 and 15 mg decreased the levels of YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 compared with baseline
4)Make truly exceptional product This feels obvious, but if people are drinking less, then theyre going to be a lot more choosy about what they do drink
Samples or Standards are added to the micro CLIA plate wells and combined with the specific antibody
As I mentioned, the first of the class, exenatide, came out in 2005, and I think people forget that we've got about 20 years under our belt of experience with these medications
